v3.21.2
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value, Financial Instruments Measured on Recurring Basis Our financial instruments measured at fair value on a recurring basis were as follows at the dates indicated:
Condensed Consolidated
Balance Sheet Caption
Fair Value at September 30, 2021
(in thousands) Level 1 Level 2 Level 3 Total
Assets:
Equity securities Other assets $ 1,268  $ —  $ —  $ 1,268 
Total Assets $ 1,268  $ —  $ —  $ 1,268 
Liabilities:
Interest rate swap contract Other long-term liabilities $ —  $ 409  $ —  $ 409 
Contingent consideration - current Accrued expenses and other current liabilities —  —  1,710  1,710 
Contingent consideration - long-term Other long-term liabilities —  —  873  873 
Total Liabilities $ —  $ 409  $ 2,583  $ 2,992 

Condensed Consolidated
Balance Sheet Caption
Fair Value at December 31, 2020
(in thousands) Level 1 Level 2 Level 3 Total
Liabilities:
Interest rate swap contract Other long-term liabilities $ —  $ 665  $ —  $ 665 
Total Liabilities $ —  $ 665  $ —  $ 665 
Schedule of Interest Rate Derivatives Details of the outstanding swap contract as of September 30, 2021, which is a "pay-fixed and receive-floating" contract, are as follows:
Swap Maturity Notional Value
(in thousands)
Pay-Fixed Rate Receive-Floating Rate Floating Rate
Reset Terms
October 1, 2025 $ 8,050  2.07750  % One-Month LIBOR Monthly
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2021 is as follows:
(in thousands) Contingent Consideration
Balance at December 31, 2020 $ — 
Contingent consideration issued for Eyce acquisition 1,828 
Loss from fair value adjustments included in results of operations 755 
Balance at September 30, 2021
$ 2,583